YOLFTbeta
47

Sunmax Biotechnology Co Ltd

4728 · TWO · Healthcare / Biotechnology

384.50TWD-3.50 (-0.90%)

Price History

Full chart

Market Stats

Previous Close388.00
Open383.50
Day Range383.50 – 385.50
52-Week Range350.00 – 416.00
Volume9.05K
Market Cap21.49B
P/E (TTM)26.53
Forward P/E30.77
EPS14.87
Dividend Yield3.07%
Beta-0.12
50-Day Avg393.20
200-Day Avg388.59

About

Sunmax Biotechnology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of biomedical-grade collagen and related products in Taiwan, Mainland China, and internationally. It offers collagen dermal filler sets, such as Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO injectable collagen gel with lidocaine. The company was founded in 2001 and is based in Tainan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ming Yi Lin
  • Employees0
  • HeadquartersNo. 10, Huandong Road, Tainan City, Taiwan, 744, Taiwan
  • Websitehttps://www.sunmaxbiotech.com

Leadership

  • Mr. Ming Yi LinManager
  • Shi Xing ZhuangAccounting Supervisor

Financials

Income Statement

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue111.65M155.53M190.13M304.07M594.14M855.85M1.04B1.40B1.69B1.82B2.03B
Growth (%)-+39.30%+22.24%+59.93%+95.40%+44.05%+21.01%+35.19%+20.64%+7.64%+11.45%
Cost of Revenue44.80M56.39M52.55M63.75M79.97M154.65M141.21M207.27M284.10M339.35M437.54M
Gross Profit66.85M99.14M137.57M240.32M514.17M701.20M894.45M1.19B1.40B1.48B1.59B
Gross Margin59.87%63.74%72.36%79.03%86.54%81.93%86.37%85.20%83.18%81.33%78.41%
Operating Expense115.95M96.05M124.30M176.39M336.66M354.76M531.81M415.12M492.43M551.70M590.32M
Operating Income-49.10M3.10M13.27M63.93M177.52M346.44M362.63M777.68M912.47M926.96M998.31M
Operating Margin-43.97%1.99%6.98%21.02%29.88%40.48%35.01%55.55%54.02%50.99%49.27%
EBITDA--22.17M71.19M171.16M380.25M418.40M835.83M985.29M1.06B1.12B
EBITDA Margin--11.66%23.41%28.81%44.43%40.40%59.70%58.34%58.22%55.36%
Net Income-44.16M1.74M16.54M74.66M100.45M238.08M245.64M533.83M625.71M679.40M725.75M
Net Income Margin-39.55%1.12%8.70%24.55%16.91%27.82%23.72%38.13%37.05%37.37%35.82%
R&D21.48M19.54M11.82M19.51M22.61M17.53M24.63M17.97M28.74M39.18M42.23M
R&D as % of Total Revenue19.24%12.57%6.22%6.42%3.81%2.05%2.38%1.28%1.70%2.16%2.08%
Interest Expense00002.74M2.92M2.81M1.34M2.94M5.95M4.88M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.46%0.34%0.27%0.10%0.17%0.33%0.24%

Balance Sheet

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets602.57M597.49M660.92M757.89M1.11B1.36B1.48B1.79B2.16B2.09B2.12B
Total Liabilities44.33M42.20M88.22M109.88M435.82M475.27M460.44M468.00M732.99M582.13M505.60M
Total Equity558.24M555.29M572.70M648.01M676.83M888.84M1.02B1.33B1.43B1.51B1.62B
Cash430.66M434.66M314.19M314.33M583.49M778.58M602.55M589.30M854.69M775.47M711.59M
Total Debt-----135.65M109.06M70.33M174.09M--
Net Debt------642.93M-493.49M-518.97M-680.61M--

Cash Flow

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-22.84M16.58M37.09M100.83M289.51M386.97M243.28M342.97M848.56M561.03M825.92M
Investing Cash Flow3.12M-4.50M-182.00M-92.07M82.18M-101.90M-285.17M----
Financing Cash Flow-52.68M-3.52M24.00M-5.17M-96.58M-95.38M-131.97M-281.21M-549.80M--
Capital Expenditure3.88M4.73M3.15M4.72M13.68M130.10M255.43M152.03M110.39M36.99M68.33M
Free Cash Flow--33.44M96.00M270.70M256.88M-12.14M190.94M738.16M524.04M757.58M
Dividends Paid32.68M16.20M16.20M16.20M65.36M81.69M108.93M239.64M517.40M599.09M631.77M
FCF to OCF--90.15%95.21%93.50%66.38%-4.99%55.67%86.99%93.41%91.73%
Dividend Paid to FCF--48.45%16.88%24.14%31.80%-896.88%125.50%70.09%114.32%83.39%

Earnings

Report DateDec 31, 2011Apr 15, 2012Aug 30, 2012
EPS Estimate0.300.270.30
EPS Actual0.290.18-0.05
Surprise-3.33%-33.33%-116.67%
Timing-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap21.49B
Enterprise Value21.10B
Trailing P/E26.53
Forward P/E30.77
Price / Sales9.79
Price / Book15.22
EPS14.87
Book Value26.27
Revenue (TTM)2.19B
Gross Profit (TTM)1.74B
EBITDA1.17B
Profit Margin36.97%
Operating Margin53.26%
Return on Equity60.67%
Return on Assets31.13%
Shares Outstanding54.46M
Shares Float27.11M
Beta-0.12
Dividend Yield3.07%
Dividend Rate12.10
Payout Ratio159.22%

Dividends

20261×
12.10Mar 31, 2026
20251×
11.60Aug 4, 2025
20241×
11.00Jul 17, 2024
20231×
9.50Jul 18, 2023
20221×
4.40Jul 13, 2022
20211×
2.00Sep 22, 2021
20201×
1.50Aug 27, 2020
20191×
1.20Aug 29, 2019
20181×
0.30Aug 23, 2018
20151×
0.61Aug 31, 2015
20141×
0.60Aug 25, 2014
20131×
0.50Aug 29, 2013
20121×
0.60Jun 26, 2012